Free Trial

iTeos Therapeutics (ITOS) News Today

iTeos Therapeutics logo
$7.38 -0.08 (-1.01%)
As of 10:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
iTeos Therapeutics, Inc. stock logo
Eversept Partners LP Buys New Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Eversept Partners LP purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 220,196 shares of the company's stock, valued at approximatel
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,830,000 shares, a growth of 33.6% from the March 15th total of 1,370,000 shares. Currently, 5.5% of the company's stock are sold short. Based on an average trading volume of 313,200 shares, the days-to-cover ratio is presently 5.8 days.
iTeos Therapeutics, Inc. stock logo
Renaissance Technologies LLC Boosts Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Renaissance Technologies LLC raised its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 56.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 837,200 shares of the company's sto
iTeos Therapeutics, Inc. stock logo
ExodusPoint Capital Management LP Invests $677,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
ExodusPoint Capital Management LP acquired a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 88,187 shares of the company's sto
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 342.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,068,796 shares of the company's stock after purchasing
iTeos Therapeutics, Inc. stock logo
Trexquant Investment LP Has $1.38 Million Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Trexquant Investment LP grew its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 267.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 179,966 shares of the company's sto
iTeos Therapeutics, Inc. stock logo
ADAR1 Capital Management LLC Has $1.01 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
ADAR1 Capital Management LLC lessened its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 65.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 131,599 shares of the company's stock after selling 245,138 shares during the period. AD
iTeos Therapeutics, Inc. stock logo
Raymond James Financial Inc. Buys New Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Raymond James Financial Inc. purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 150,967 shares of the company's st
iTeos Therapeutics (ITOS) Gets a Buy from Piper Sandler
iTeos Therapeutics, Inc. stock logo
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 19.0%
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 1,280,000 shares, a decline of 19.0% from the February 13th total of 1,580,000 shares. Based on an average daily trading volume, of 362,400 shares, the short-interest ratio is presently 3.5 days. Approximately 3.9% of the shares of the stock are sold short.
iTeos Therapeutics, Inc. stock logo
HC Wainwright Issues Optimistic Estimate for ITOS Earnings
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at HC Wainwright increased their Q1 2025 earnings estimates for iTeos Therapeutics in a research report issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per sha
iTeos Therapeutics, Inc. stock logo
Research Analysts Offer Predictions for ITOS Q1 Earnings
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued on Wednesday, March 5th. Wedbush analyst D. Nierengarten now anticipates that the company wil
iTeos Therapeutics, Inc. stock logo
FY2029 Earnings Estimate for ITOS Issued By HC Wainwright
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of iTeos Therapeutics in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth anticipates that the comp
iTeos Therapeutics, Inc. stock logo
Wells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price
Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Given New $15.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. decreased their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Receives Outperform Rating from Wedbush
Wedbush reissued an "outperform" rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Announces Quarterly Earnings Results
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (ITOS) to Release Earnings on Wednesday
iTeos Therapeutics (NASDAQ:ITOS) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.
iTeos Therapeutics, Inc. stock logo
Peapod Lane Capital LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Peapod Lane Capital LLC purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 108,853 shares of the company's stock, valued at approximately $836,000. Peapod Lane Ca
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in January
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 1,500,000 shares, a drop of 21.1% from the December 31st total of 1,900,000 shares. Approximately 4.9% of the shares of the company are short sold. Based on an average daily volume of 556,500 shares, the days-to-cover ratio is currently 2.7 days.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in December
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,500,000 shares, a drop of 21.1% from the December 15th total of 1,900,000 shares. Based on an average daily volume of 556,500 shares, the short-interest ratio is presently 2.7 days. Currently, 4.9% of the company's shares are short sold.
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday.
iTeos Therapeutics outlines business updates, strategies for 2025
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at Wedbush
Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Friday.
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
iTeos Therapeutics, Inc. stock logo
State Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
State Street Corp increased its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 21.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,175,353 shares of the company's stock after buying an additional 211,452 shares during the quarter. Sta
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics (NASDAQ:ITOS) Price Target Lowered to $19.00 at Wells Fargo & Company
Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday.
iTeos Therapeutics, Inc. stock logo
HC Wainwright Reiterates "Buy" Rating for iTeos Therapeutics (NASDAQ:ITOS)
HC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research note on Friday.
iTeos Therapeutics, Inc. stock logo
RA Capital Management L.P. Sells 332,548 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)
RA Capital Management L.P. lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,184,711 shares of the company's stock after selling 332,
iTeos Therapeutics, Inc. stock logo
Readystate Asset Management LP Has $1.73 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Readystate Asset Management LP raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 97.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,819 shares of the company's stock after acquiring an ad
iTeos Therapeutics, Inc. stock logo
Vestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)
Vestal Point Capital LP trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 41.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,025,000 shares of the company's stock after selling 725,00
iTeos Therapeutics, Inc. stock logo
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLC
Algert Global LLC grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 92.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,139 shares of the company's stock after buying a
iTeos to Participate in Upcoming Investor Conferences
Get iTeos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.

ITOS Media Mentions By Week

ITOS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ITOS
News Sentiment

1.21

0.74

Average
Medical
News Sentiment

ITOS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ITOS Articles
This Week

4

2

ITOS Articles
Average Week

Get iTeos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ITOS) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners